The Division of Medical Screening and Special Testing, part of the Department of Pathology and Laboratory Medicine, offers specialized laboratory testing in prenatal screening, reproductive endocrinology, and women's health, with the highest quality, rapid turnaround and reasonable cost.
From research to clinical practice, our laboratory has developed both a national and international reputation in these areas of testing. We were involved in the development of, and were the first academic program in the U.S. to offer the Quad test for prenatal screening. We also served as the central laboratory in the FASTER Trial, a large-scale, national intervention trial sponsored by the National Institutes of Health (NIH) to compare first and second trimester screening methods. We have now implemented a new generation of screening using cell-free DNA in maternal plasma.
Our laboratory is among the most experienced in the U.S. in the measurement of inhibin A and related proteins, and was the first to report on the use of inhibin types in prenatal screening and testing for ovarian reserve.
Women & Infants Hospital Medical Screening and Special Testing
70 Elm Street
Providence, RI 02905
P: (401) 453-7650
Monday - Friday 7:30 a.m. to 4:30 p.m.
Call (401) 453-7650 for help finding a location convenient for you
It is a blood test done between the 15th and 20th weeks of pregnancy that allows us to measure certain substances that come from the developing fetus and placenta and are present in a mother’s blood.
AMH is a normal product of developing ovarian follicles. The amount of AMH measured in serum during the start of a new menstrual cycle is directly related to the number and health of small growing follicles.
Women & Infants Hospital Prenatal Diagnosis Center, in collaboration with our Division of Prenatal and Special Testing, offers additional prenatal screenings for Down syndrome: two nuchal translucency (NT) based screening tests.
Down syndrome is caused by the presence of an extra chromosome number 21 in the cells of the developing baby.
Preeclampsia is a common medical condition in pregnancy that can harm you and/or your unborn baby. One pregnant woman in about 25 will develop preeclampsia. Any pregnant woman can get preeclampsia, but some women have an increased risk.
Our staff of pathologists, program coordinators, medical technologists, research technicians, and clerical workers are dedicated to providing the highest level of quality and support available anywhere. We are available seven days a week to answer your calls.
Dr. Lambert-Messerlian is the director of the Division of Medical Screening and Special Testing and a professor in the Department of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University. She has a national and international reputation for her studies of the inhibin and activin family of gonadal and placental hormones, and was involved in the first studies in the U.S. on the clinical use of inhibin A in prenatal screening for Down syndrome and inhibin B in assessment of ovarian reserve. She is the author or coauthor of more than 100 research studies, review articles and scientific abstracts.
Dr. Palomaki is an associate director of the division and associate professor in the Department of Pathology and Laboratory Medicine at The Warren Alpert Medical School of Brown University. He has received grant and contract support in the areas of prenatal screening and genetic testing, directed or participated in several structured evidence reviews, authored more than 250 peer-reviewed articles, and lectured on genetics and prenatal screening to national and international audiences.
Diane S. Panizza has been the supervisor of the division's laboratory since 1985. She is an expert in all facets of hormone and tumor marker assays, prenatal screening tests, and interpretation of test results. Ms. Panizza is one of the most knowledgeable laboratory professionals inthe area of prenatal screening and hormone assays and is a great resource to laboratory professionals throughout the U.S.